Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
OPTIMIZERx Corp (OPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: OPRX (2-star) is a SELL. SELL since 1 days. Profits (65.44%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.67
1 Year Target Price $15.67
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 96.23% | Avg. Invested days 52 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 249.68M USD | Price to earnings Ratio - | 1Y Target Price 15.67 |
Price to earnings Ratio - | 1Y Target Price 15.67 | ||
Volume (30-day avg) 7 | Beta 1.33 | 52 Weeks Range 3.78 - 15.71 | Updated Date 06/30/2025 |
52 Weeks Range 3.78 - 15.71 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.33% | Operating Margin (TTM) -9.64% |
Management Effectiveness
Return on Assets (TTM) -1.2% | Return on Equity (TTM) -12.91% |
Valuation
Trailing PE - | Forward PE 23.53 | Enterprise Value 268500314 | Price to Sales(TTM) 2.65 |
Enterprise Value 268500314 | Price to Sales(TTM) 2.65 | ||
Enterprise Value to Revenue 2.85 | Enterprise Value to EBITDA -16.77 | Shares Outstanding 18495100 | Shares Floating 14245119 |
Shares Outstanding 18495100 | Shares Floating 14245119 | ||
Percent Insiders 14.98 | Percent Institutions 66.27 |
Analyst Ratings
Rating 3 | Target Price 15.67 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
OPTIMIZERx Corp
Company Overview
History and Background
OPTIMIZERx Corp, founded in 2006, provides digital health solutions for pharmaceutical manufacturers, healthcare providers, and patients. It initially focused on patient engagement programs and has expanded into broader medication access and adherence solutions.
Core Business Areas
- Therapeutic Support: Provides therapeutic support services, including medication access and adherence programs, patient education resources, and financial assistance solutions, to improve patient outcomes and adherence to prescribed therapies.
- Digital Health Platform: A digital health platform connecting pharmaceutical manufacturers, healthcare providers, and patients. It facilitates communication, provides access to educational materials, and supports medication adherence through various digital tools.
Leadership and Structure
David Worthen serves as the CEO. The company operates with a functional organizational structure, with departments dedicated to sales, marketing, product development, and customer support.
Top Products and Market Share
Key Offerings
- Therapeutic Resource Centers: Offers a virtual hub for patients needing access and adherence help for specialty medications. There is no direct market share readily available. Competitors include ConnectiveRx, TrialCard, and CoverMyMeds.
- eSampling and Voucher Programs: Provides digital platforms for pharmaceutical manufacturers to distribute samples and vouchers directly to healthcare providers and patients. There is no direct market share readily available. Competitors include ConnectiveRx, TrialCard, and Eversana.
Market Dynamics
Industry Overview
The pharmaceutical services industry is growing, driven by increasing demand for patient support programs, medication adherence solutions, and digital health tools. The industry is becoming increasingly competitive, with numerous players offering similar services.
Positioning
OPTIMIZERx Corp positions itself as a leading provider of therapeutic support and digital health solutions, leveraging its technology platform and expertise in patient engagement and medication adherence to gain a competitive edge.
Total Addressable Market (TAM)
The global market for digital health solutions in the pharmaceutical industry is estimated to reach $225 billion by 2025. OPTIMIZERx is positioned to capitalize on this large TAM through its innovative digital offerings.
Upturn SWOT Analysis
Strengths
- Strong relationships with pharmaceutical manufacturers
- Proprietary digital health platform
- Expertise in patient engagement and medication adherence
- Data-driven insights and analytics
Weaknesses
- Concentration of revenue from a few large clients
- Limited international presence
- Vulnerability to changes in pharmaceutical pricing and reimbursement policies
- Relatively small market capitalization
Opportunities
- Expansion into new therapeutic areas
- Development of new digital health solutions
- Strategic acquisitions
- International expansion
Threats
- Increased competition
- Changes in healthcare regulations
- Economic downturn
- Cybersecurity threats
Competitors and Market Share
Key Competitors
- CRGX
- EVSN
- TCMD
Competitive Landscape
OPTIMIZERx Corp competes with other digital health companies in a fragmented market. The company differentiates itself through its focus on therapeutic support and its proprietary digital health platform.
Major Acquisitions
Patient Access Solutions, Inc.
- Year: 2018
- Acquisition Price (USD millions): 38
- Strategic Rationale: Expanded OPTIMIZERx's reach and capabilities in patient access solutions.
Growth Trajectory and Initiatives
Historical Growth: OPTIMIZERx Corp has experienced strong revenue growth in recent years, driven by increasing demand for its therapeutic support and digital health solutions.
Future Projections: Analysts project continued revenue growth for OPTIMIZERx Corp, fueled by expansion into new markets and the development of innovative products.
Recent Initiatives: OPTIMIZERx Corp has recently launched new digital health solutions and expanded its partnerships with pharmaceutical manufacturers.
Summary
OPTIMIZERx Corp demonstrates growth through its digital health platform and therapeutic support programs. Its strong relationships with pharmaceutical manufacturers are crucial for continued expansion. However, reliance on a few major clients poses a risk, and competition within the industry necessitates constant innovation to maintain its market position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Investor Presentations
- Analyst Reports
- Industry Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is dynamic, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OPTIMIZERx Corp
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 1996-10-22 | President & CEO Mr. Stephen L. Silvestro | ||
Sector Healthcare | Industry Health Information Services | Full time employees 128 | Website https://www.optimizerx.com |
Full time employees 128 | Website https://www.optimizerx.com | ||
OptimizeRx Corporation operates as a digital healthcare technology company. The company offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, HUB awareness, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. It also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.